{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:18:32Z","timestamp":1769260712177,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 226 clinical trial protocols identified from the\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      database were systematically reviewed by five researchers. Data on trial and PE characteristics were extracted, including frequency and timing, purpose, elements and conduct of PE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 211 protocols (59% phase 3, 72% two\u2010arm trials) were reviewed. Of these, 190 protocols mentioned a PE, and by distinguishing between different types of PE, a total of 241 PEs were assessed. Of the 190 protocols, 65% of protocols explicitly documented the purpose(s) for conducting a PE. PE was most often explicitly documented to identify adverse events (40%), followed by assessment of trial endpoints (33%), eligibility (21%), overall health status (3%) and characterization of the study population (1%). Sixty per cent of PEs described what was to be examined, and 8% specified how the PE should be conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Protocols often lacked information on the purpose, elements and conduct of the PE, which may negatively impact the consistency of clinical trials. With the purpose of PE being often not explicitly stated, it can be questioned whether a PE is needed in every clinical trial or if it is performed as a matter of routine. Future research is needed to investigate whether PE is always necessary in a clinical trial and to explore opportunities for PE in clinical trial innovations including decentralization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70258","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T03:35:41Z","timestamp":1756784141000},"page":"280-290","source":"Crossref","is-referenced-by-count":0,"title":["Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-0807","authenticated-orcid":false,"given":"Julia","family":"Kopanz","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-7032","authenticated-orcid":false,"given":"Amy","family":"Rogers","sequence":"additional","affiliation":[{"name":"MEMO Research, Division of Cardiovascular Research University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"P\u00e9rez\u2010Breva","sequence":"additional","affiliation":[{"name":"Vaccine Research. Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunitat Valenciana (FISABIO)\u2010Public Health  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Hall","sequence":"additional","affiliation":[{"name":"MEMO Research, Division of Cardiovascular Research University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashasthi","family":"Devaiah","sequence":"additional","affiliation":[{"name":"MEMO Research, Division of Cardiovascular Research University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-7127","authenticated-orcid":false,"given":"Isla S.","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"MEMO Research, Division of Cardiovascular Research University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Lagerwaard","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira G. P.","family":"Zuidgeest","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Trials@Home consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"37","volume-title":"Clinical methods: the history, physical, and laboratory examinations","author":"Campbell EW","year":"1990"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480190092040"},{"issue":"2","key":"e_1_2_12_4_1","first-page":"163","article-title":"Contributions of the history, physical examination, and laboratory investigation in making medical diagnoses","volume":"156","author":"Peterson MC","year":"1992","journal-title":"West J Med"},{"key":"e_1_2_12_5_1","volume-title":"Clinical examination: a systematic guide to physical diagnosis","author":"Talley NJ","year":"2010"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480190080037"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010010\u20101400\u20103"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.06.004"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.12.007"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2777"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed\u20102017\u2010110886"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.01.023"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.zefq.2015.01.003"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103520"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6565"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldad022"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1441"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2018.06.008"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15205"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11673\u2010024\u201010341\u20103"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441\u2010019\u201000006\u20104"},{"key":"e_1_2_12_22_1","unstructured":"Castor.Electronic Data Capture (EDC).2023. Accessed January 30 2025.https:\/\/www.castoredc.com\/"},{"key":"e_1_2_12_23_1","volume-title":"RStudio: integrated development environment for R. Posit software","author":"Posit team","year":"2024"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2420"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.4.1177"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.12.004"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010155\u20108\u2010201110180\u201000013"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063\u2010020\u20104197\u20103"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70070"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431\u2010016\u20102715\u20109"},{"key":"e_1_2_12_31_1","unstructured":"European Medicines Agency.ICH Guideline for Good Clinical Practice E6(R2).2016. Accessed January 30 2025.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5-revision-2_en.pdf"},{"key":"e_1_2_12_32_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.ICH Harmonised Guideline: General Considerations for Clinical Studies E8(R1).2021. Accessed January 30 2025.https:\/\/database.ich.org\/sites\/default\/files\/E8-R1_Guideline_Step4_2021_1006.pdf"},{"key":"e_1_2_12_33_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry.2018. Accessed January 30 2025.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u2010S004"},{"key":"e_1_2_12_35_1","unstructured":"European Union.Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data and Repealing Directive 95\/46\/EC (General Data Protection Regulation).2016. Accessed January 30 2025.https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32016R0679"},{"key":"e_1_2_12_36_1","unstructured":"European Union.Regulation (EU) 2018\/1725 of the European Parliament and of the Council of 23 October 2018 on the Protection of Natural Persons with Regard to the Processing of Personal Data by the Union Institutions Bodies Offices and Agencies and on the Free Movement of Such Data and Repealing Regulation (EC) No 45\/2001 and Decision No 1247\/2002\/EC.2018. Accessed January 30 2025.https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32018R1725"},{"key":"e_1_2_12_37_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.ICH Harmonised Guideline: A Selective Approach to Safety Data Collection in Specific Late\u2010Stage Pre\u2010Approval or Post\u2010Approval Clinical Trials E19.2022. Accessed January 30 2025.https:\/\/database.ich.org\/sites\/default\/files\/ICH_E19_Guideline_Step4_2022_0826_0.pdf"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010011\u20101937\u20109"},{"key":"e_1_2_12_39_1","unstructured":"World Health Organization.Handbook for Good Clinical Research Practice (GCP): Guidance for Implementation.2005. Accessed January 30 2025.https:\/\/iris.who.int\/bitstream\/handle\/10665\/43392\/924159392X_eng.pdf"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:35:55Z","timestamp":1769146555000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bcp.70258"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70258","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}